The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis

The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis

Abstract Background Patients with inflammatory bowel disease (IBD) present with reduced serum insulin-like growth factor I (IGF-I). Anti-inflammatory treatment with prednisolone or infliximab ameliorates symptoms and increases circulating IGF-I, but prednisolone induces catabolism, whereas inflixima...

Full description

Bibliographic Details
Main Authors: Rikke Hjortebjerg, Karen L. Thomsen, Jørgen Agnholt, Jan Frystyk
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Gastroenterology
Subjects:
IGF binding protein-4
Inflammatory bowel disease
Infliximab
Prednisolone
Pregnancy-associated plasma protein-a
Stanniocalcin-2
Online Access:http://link.springer.com/article/10.1186/s12876-019-1000-6

Internet

http://link.springer.com/article/10.1186/s12876-019-1000-6

Similar Items